THE WOODLANDS, Texas,
Nov. 4, 2014 /PRNewswire/
-- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced
today management additions directed towards the completion of Phase
3 development and commercial preparations for telotristat etiprate
in carcinoid syndrome and preparation for Phase 3 initiation and
commercial readiness for sotagliflozin (LX4211) in type 1
diabetes.
Clinical Operations and Clinical
Development
Kenneth B.
Kassler-Taub, M.D. has joined Lexicon as vice president of
clinical operations, with responsibility for managing the execution
of all of the company's clinical trials. Dr. Kassler-Taub
brings to Lexicon more than 25 years' experience, most recently
with Becton Dickinson and Company,
where he was vice president, corporate clinical development
overseeing the clinical development function company-wide, and
where he earlier served as worldwide vice president, medical
affairs, BD Medical Segment. Before joining Becton Dickinson, Dr. Kassler-Taub worked for 14
years at Bristol-Myers Squibb Company, where he served in a series
of roles including vice president, global pharmacovigilance,
epidemiology and risk management, global clinical sciences, and
vice president, clinical affairs, worldwide clinical research and
development.
Commercial Operations
Kiernan
A. Seth, Ph.D., MBA has joined Lexicon as executive director
of marketing with responsibility for helping advance Lexicon's
commercial readiness. Dr. Seth brings to Lexicon more than 19
years' experience. His most recent experience was from Eisai,
Inc., where he served as executive director, Eisai Value
Maximization Systems and head of the oncology business unit.
Before joining Eisai, Dr. Seth served in a series of marketing
roles with Bristol-Myers Squibb, Pfizer and Schering-Plough
involving products in oncology, cardiovascular and metabolic
disease, immunology and central nervous system disorders. Dr.
Seth will report directly to John
Northcott, Lexicon's vice president of marketing, commercial
strategy and operations.
"The addition of Dr. Kassler-Taub further strengthens our
organization in clinical operations as we make our final push
toward completion of our Phase 3 program for telotristat etiprate
in carcinoid syndrome and begin our Phase 3 program with
sotagliflozin (LX4211) in type 1 diabetes," said Lonnel Coats, Lexicon's president and chief
executive officer. "Dr. Seth will be a great complement to
our commercial team as we establish Lexicon's commercial
presence."
About Lexicon
Lexicon is a biopharmaceutical company
focused on developing breakthrough treatments for human
disease. Lexicon has clinical-stage drug programs for
diabetes, carcinoid syndrome, and other indications, all of which
were discovered by Lexicon's research team. Lexicon has used
its proprietary gene knockout technology to identify more than 100
promising drug targets. For additional information about
Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains
"forward-looking statements," including statements relating to
Lexicon's clinical development of sotagliflozin (LX4211) and
telotristat etiprate (LX1032), including characterizations of the
results of and projected timing of clinical trials and the
potential therapeutic and commercial potential of sotagliflozin and
telotristat etiprate. In addition, this press release also
contains forward-looking statements relating to Lexicon's growth
and future operating results, discovery and development of
products, strategic alliances and intellectual property, as well as
other matters that are not historical facts or information.
All forward-looking statements are based on management's current
assumptions and expectations and involve risks, uncertainties and
other important factors, specifically including those relating to
Lexicon's ability to meet its capital requirements, successfully
conduct clinical development of sotagliflozin and telotristat
etiprate and preclinical and clinical development of its other
potential drug candidates, obtain necessary regulatory approvals,
achieve its operational objectives, obtain patent protection for
its discoveries and establish strategic alliances, as well as
additional factors relating to manufacturing, intellectual property
rights, and the therapeutic or commercial value of its drug
candidates, that may cause Lexicon's actual results to be
materially different from any future results expressed or implied
by such forward-looking statements. Information identifying
such important factors is contained under "Risk Factors" in
Lexicon's annual report on Form 10-K for the year ended
December 31, 2013, as filed with the
Securities and Exchange Commission. Lexicon undertakes no
obligation to update or revise any such forward-looking statements,
whether as a result of new information, future events or
otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.